Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Malignancies: early-phase trial registry
3 of 7 indexed Advanced Solid Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Advanced Solid Malignancies: 7 US clinical trials tracked, 3 recruiting.
Advanced Solid Malignancies is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Millennium Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-solid-malignancies
OPEN 3 | RECR 43% | LATE 0 | EARLY 7 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
Advanced Solid Malignancies lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Malignancies is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Malignancies trials is spread across many organizations.
Millennium Pharmaceuticals accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Malignancies enrolment sits around 170 participants.
Median target enrolment is 170 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.
-
Advanced Solid Malignancies research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
NCT05417594
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
NCT07223047
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Georgiamune
NCT06028074
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Treadwell Therapeutics
NCT04521413
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co.
NCT05159700
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
NCT06760481
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Millennium Pharmaceuticals
NCT01058707
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Malignancies page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Advanced Solid Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Millennium Pharmaceuticals sponsors the most Advanced Solid Malignancies trials on record, review their full trial history before evaluating a specific study. See Millennium Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Malignancies condition card totals 7 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.